| __timestamp | Gilead Sciences, Inc. | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2983000000 | 1244910 |
| Thursday, January 1, 2015 | 3426000000 | 5029636 |
| Friday, January 1, 2016 | 3398000000 | 4846776 |
| Sunday, January 1, 2017 | 3878000000 | 5329003 |
| Monday, January 1, 2018 | 4056000000 | 7121000 |
| Tuesday, January 1, 2019 | 4381000000 | 9128000 |
| Wednesday, January 1, 2020 | 5151000000 | 10731000 |
| Friday, January 1, 2021 | 5246000000 | 10701000 |
| Saturday, January 1, 2022 | 5673000000 | 16121000 |
| Sunday, January 1, 2023 | 6090000000 | 37021000 |
| Monday, January 1, 2024 | 6091000000 |
Unveiling the hidden dimensions of data
In the competitive world of biotechnology, managing operational costs is crucial for success. Gilead Sciences, Inc. and Viking Therapeutics, Inc. offer a fascinating study in contrasts over the past decade. From 2014 to 2023, Gilead's Selling, General, and Administrative (SG&A) expenses surged by over 100%, peaking at approximately $6 billion in 2023. This reflects Gilead's expansive growth strategy and its commitment to maintaining a robust market presence. In stark contrast, Viking Therapeutics, a smaller player, saw its SG&A expenses grow by nearly 3,000%, reaching around $37 million in 2023. This dramatic increase underscores Viking's aggressive push to scale operations and enhance its market footprint. Despite the disparity in absolute numbers, both companies illustrate the dynamic nature of SG&A management in the biotech sector, highlighting the balance between cost control and strategic investment.
Novartis AG and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Neurocrine Biosciences, Inc.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Opthea Limited
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Xenon Pharmaceuticals Inc.
Insmed Incorporated or Viking Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Madrigal Pharmaceuticals, Inc. and Viking Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Viking Therapeutics, Inc. and Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Comparing SG&A Expenses: Viking Therapeutics, Inc. vs MannKind Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Viking Therapeutics, Inc. and Xencor, Inc.